Immunophotonics is pioneering the field of Interventional Immunology-Oncology™, where a single injection of IP-001 –seamlessly integrated into the clinical workflow– has the potential to transform a routine tumor ablation into a systemic immunotherapy to fight cancer throughout the body.
Immunophotonics co-founders Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President are pleased to announce a collaboration with CIRSE, The Cardiovascular and Interventional Radiological Society of Europe, to support preparations for a groundbreaking Phase 2/3 clinical trial: INJECTABL-3. The trial will be managed by CIRSE’s contract research organization, Next Research. INJECTABL-3 is intended to assess if IP-001 can extend progression-free survival and overall survival in patients receiving standard of care, curative-intent tumor ablation.
Immunophotonics would like to extend our thanks to: CIRSE, next research, Philippe Pereira, Uwe Martens, Markus Joerger, Martijn Meijerink, Hester Scheffer, Constantinos “Costi” Sofocleous, Patrick Knüsel, Thomas Helmberger, Martin Fuchs, and Danielle Vos
Special recognition is also due to Nathalie Kaufmann, Claire Poulet, Petra Mann and the rest of the CIRSE team for their tireless efforts.
Together we strive to push the boundaries of cancer care and improve patient outcomes worldwide.
